Mechanisms of the antinociceptive action of (−) Epicatechin obtained from the hydroalcoholic fraction of Combretum leprosum Mart & Eic in rodents by Luciano da Lopes et al.
Lopes et al. Journal of Biomedical Science 2012, 19:68
http://www.jbiomedsci.com/content/19/1/68RESEARCH Open AccessMechanisms of the antinociceptive action of (−)
Epicatechin obtained from the hydroalcoholic
fraction of Combretum leprosum Mart & Eic
in rodents
Luciano da Silva Lopes1*, Rosemarie Brandin Marques1, Heliana Barros Fernandes1, Sergio da Silva Pereira1,
Mariane CC Ayres2, Mariana Helena Chaves2 and Fernanda RC Almeida1Abstract
Background: The mechanisms of the antinociceptive activity of (−) epicatechin (EPI), a compound isolated from
the hydroalcoholic fraction of Combreum leprosum Mart & Eicher.
Methods: were assessed in the model of chemical nociception induced by glutamate (20 μmol/paw). To evaluate
the mechanisms involved, the animals , male Swiss mice (25-30 g), received EPI (50 mg/kg p.o.) after pretreatment
with naloxone (2 mg/kg s.c. opioid antagonist), glibenclamide (2 mg/kg s.c. antagonist K + channels sensitive to
ATP), ketanserin (0.3 mg/kg s.c. antagonist of receptor 5-HT2A), yoimbine (0.15 mg/kg s.c. α2 adrenergic receptor
antagonist), pindolol (1 mg/kg s.c. 5-HT1a/1b receptor antagonist), atropine (0.1 mg/kg s.c. muscarinic antagonist)
and caffeine (3 mg/kg s.c. adenosine receptor antagonist), ondansetron (0.5 mg/kg s.c. for 5-HT3 receptor) and
L-arginine (600 mg/kg i.p.).
Results: The antinociceptive effect of EPI was reversed by pretreatment with naloxone and glibenclamide,
ketanserin, yoimbine, atropine and pindolol, which demonstrates the involvement of opioid receptors and
potassium channels sensitive to ATP, the serotoninergic (receptor 5HT1A and 5HT2A), adrenergic (receptor alpha 2)
and cholinergic (muscarinic receptor) systems in the activities that were observed. The effects of EPI, however, were
not reversed by pretreatment with caffeine, L-arginine or ondansetron, which shows that there is no involvement
of 5HT3 receptors or the purinergic and nitrergic systems in the antinociceptive effect of EPI. In the Open Field and
Rotarod test, EPI had no significant effect, which shows that there was no central nervous system depressant or
muscle relaxant effect on the results.
Conclusions: This study demonstrates that the antinociceptive activity of EPI in the glutamate model involves the
participation of the opioid system, serotonin, adrenergic and cholinergic.
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One of the most noteworthy chemical constituents of
Combretum leprosum Mart & Eic is (−) epicatechin
(Figure 1). Is a flavanol belonging to the catechin fam-
ily and is commonly present in monomeric and/or oli-
gomeric forms in green teas and red wine. A flavonoid
known mainly for its antioxidant, cardioprotective,
anti-inflammatory and antineoplastic properties [1-6].
However, previous studies have shown that this class
of substances has the ability to block some subtypes of
sodium channels including neuronal cells in vitro, which
could be related to possible antinociceptive properties
[7-9]. Other studies have shown that polyphenolic com-
pounds have inhibitory properties on the formation of
nitric oxide, an important gauge of the phenomena
involved in nociception [10]. It is interesting to note that
hardly any studies in the literature have assessed the ac-
tion of (−) epicatechin in nociception models in vivo.
Previous experiments conducted in our laboratory,
demonstrated this analgesic effect of EPI in different
chemical models of nociception, in models of capsaicin,
writhing induced by acetic acid, formalin and glutamate
in mice. However, the mechanisms involved in this effect
of EPI are not known. On this basis, the objective of this
study was to evaluate the possible mechanisms involved
in the antinociceptive action of EPI in a model of chem-
ical nociception.Method
Aminals
Male Swiss mice (25-30 g) were kept at a temperature of
25 °C in a light/dark cycle of 12 hours with food and
water ad libitum. Food was withdrawn 12 hours before
the experiments. The animals were taken to the labora-
tory 2 hours before the experiments in order to adapt to
the environment. The protocols were approved by the
Ethics in Research Committee of the Federal University
of Piauí - UFPI (No. 011/2008). The experiments were
performed after approval of the protocol by the Institu-
tional Ethics Committee and were carried out in accord-
ance with the National Institutes of Health Guide forFigure 1 Chemical struture of (−) Epicatechin.Care and Use of Laboratory Animals (Publication No.
85–23, revised 1985) and the Ethical Guidelines for
Investigations of Experimental Pain in Conscious Ani-
mals (Zimmermann, 1983). The numbers of animals and
intensities of noxious stimuli used were the minimum
necessary to demonstrate the consistent effects of the
drug treatments. The tests took place at the Medicinal
Plants Research Center (NPPM), UFPI.
Obtaining the plant
The Combretum leprosum was collected from the prem-
ises of the Centre for Agrarian Sciences, Federal University
of Piauí (UFPI) during September 2007 (5°02'57.28"S, 42°
46'43.27" W, 93 meters above sea level). After collec-
tion, the species was identified and deposited at the
Graziela Barroso Herbarium and numbered 011/2008
at the UFPI.
Drugs
The experiments used: naloxone (opioid antagonist,
2 mg/kg s.c. - Sigma, USA), glibenclamide (potassium
channel antagonist-sensitive to ATP, 2 mg/kg s.c. -
Sigma, USA), caffeine (adenosine antagonist, 3 mg/kg s.c.),
ondansetron (5 HT3 antagonist, 0.3 mg/kg s.c. - Sigma,
USA) pindolol (5 HT1 antagonist - beta adrenergic
0.1 mg/kg s.c. - Sigma, USA), ketanserin (5HT 2A an-
tagonist, 0.3 mg/kg s.c.), atropine (muscarinic antag-
onist, 0.01 mg/kg s.c. - Sigma, USA), morphine (opioid
agonist 2.5 or 5 mg/kg s.c. - Cristália, BRA), MK 801
(glutamate receptor antagonist, 0.03 mg/kg i.p. - Sigma,
USA), L-arginine (precursor of nitric oxide 600 mg/kg
i.p. - Sigma, USA), L-nitro arginine (an inhibitor of ni-
tric oxide synthesis, 75 mg/kg i.p. - Sigma, USA), gluta-
mate (excitatory amino acid, 20 mol/paw, Sigma, USA)
and pindolol (beta-adrenergic and 5HT1 antagonist,
0.15 mg/kg s.c.). All substances used were dissolved in
saline except for the EPI, which was dissolved in saline
and dimethyl sulfoxide (DMSO 1 %) and used orally (p.o.).
All protocols were carried out 60 min after the admin-
istration of EPI, which according to the literature, co-
incides with the peak plasmatic concentration of this
substance [11].
Obtaining the epicatechin
Dried and powdered barks (1196 g) of C. leprosum were
extracted six times by maceration with ethanol at room
temperature (123 g, 10.3 %). The solvent was removed
by evaporation under reduced pressure and part of the
extract (95 g) was suspended in a mixture of H2O/
MeOH (2:1) and subjected to partition with ethyl acetate
afforded H2O/MeOH (27.0 g, 28.4 %) and EtAcO frac-
tions. The latter was concentrated and suspended in
MeOH/H2O (9:1), extracted with hexane, providing the
hexane (7.0 g, 7.4 %), and hydroalcoholic (52.0 g, 54.7 %)
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applied on a column (4.5 X 55 cm) of silica gel eluted
with CHCl3/MeOH, in order to increase polarity, giving
139 fractions (125 ml each). Fraction G (56–79, 438 mg,
CHCl3/MeOH 9:1) was applied to a RP-18 column
(10 g) using a H2O/MeOH (6:4) solvent system to afford
G2 (315 mg). This fraction was re-purified on a column
of Sephadex LH-20, eluted with MeOH (100 %) to yield
(−)-epicatechin (135 mg), identified by 1H and 13 C
NMR spectroscopic analyses and comparison with the
values in the literature (Galotta, et al., 2008). Absolute
configuration of the epicatechin was determined by cir-
cular dichroism. The spectrum data and chemical struc-
ture of the chemical compound are as follows: (−)
Epicatechin. Amorphous solid (135 mg, 0.14 %). CD:
ΔE220–240 +26.20, ΔE280 -0.52. RMN
1H [300 MHz,
CD3OD, δ (ppm)]: 4.81 (br s, H-2); 4.18 (br s, H-3); 2.74
(dd; J= 16.5 e 3.0 Hz; H-4anti); 2.86 (dd; J= 16.5 e
4.5 Hz; H-4syn); 5.96 (d; J= 2.0 Hz; H-6); 5.90 (d;
J= 2.0 Hz; H-8); 6.98 (d, J= 2.0 Hz; H-2’); 6.76 (d;
J= 8.0 Hz; H-5’); 6.80 (dd; J= 2.0 e 8.0 Hz; H-6’). RMN
13C [75 MHz, CD3OD, δ (ppm)]: 79.9 (C-2); 67.5 (C-3);
29.2 (C-4); 157.6 (C-5); 95.9 (C-6); 158.0 (C-7); 96.4 (C-
8); 157.3 (C-9); 100.1 (C-10); 132.3 (C-1’); 115.3 (C-2’);
145.9 (C-3’); 145.8 (C-4’); 115.9 (C-5’); 119.4 (C-6’).
In summary, the ethanol extract was fractionated in an
aqueous phase and an ethyl acetate phase, which in turn
was fractionated in the hexane and hydroalcohol phases
where the (−) epicatechin was obtained for use in the
chemical nociception protocols.Assessment of the mechanism of EPI’s antinociceptive
activity
The mechanisms involved in the antinociceptive activity
of EPI were investigated in the glutamate test, a model
of chemical nociception. The dose of EPI used was
obtained by constructing dose curves that were previ-
ously carried out at our laboratory. The lowest effective
dose of EPI was used. The doses of controls were deter-
mined according to previous experiments in our labora-
tory. The control groups received the vehicle (0.1 ml/10 g)
used for the dissolution of EPI administered orally (p.o.)
or MK 801 0.03 mg/kg administered intraperitoneally
(i.p.).
The glutamate test was carried out according to Beirith
et al., (1998). The animals (n = 6–8) were treated with
EPI (50 mg/kg p.o.) or vehicle (0.1 mL/10 g) 60 min be-
fore the intra-plantar (i.pL.) glutamate (20 μmol/paw) in-
jection. The time (s) of licking or biting the paw that
received the stimulation for 15 minutes was quantified.
The MK 801 (0.03 mg/kg i.p.) was administered 30 min
before stimulation and used as a positive control. For
the analysis of possible mechanisms of EPI activity indifferent systems, the animals were pretreated with dif-
ferent antagonists.
The antagonists were used subcutaneously 20 minutes
before EPI administration. In order to evaluate the par-
ticipation of the opioid system, potassium channels sensi-
tive to ATP, the serotoninergic, muscarinic, puri nergic
system and nitric oxide pathways, the animals received
naloxone (2 mg/kg), glybeclamide (2 mg/kg), ondanse-
tron (0.5 mg/kg), ketanserin (0.3 mg/kg) and pindolol
(1 mg/kg) yoimbina (1 mg/kg), atropine (0.01 mg/kg),
caffeine (3 mg/kg) and L-arginine (600 mg/kg), respectively.
Assessment of impairment of motor activity from EPI
The Open Field (30x30x15) and Rotarod tests were car-
ried out to eliminate the interference of the muscle re-
laxant or central depressant effect on the antinociceptive
activity of EPI, observing the number of quadrants
invaded during 5 min and the length of time on a rotat-
ing bar at 12 rpm, 60 minutes after administration of
EPI (50 mg/kg p.o.), diazepam (4 mg/kg i.p.) or vehicle
(0.1 mL/10 g v.o.). In the Rotarod test, the maximum
time of permanence on the rotating bar was 60 seconds.
The animals were screened 24 hours before the experi-
ment, and we selected those who managed to stay for 2
periods of 60 min on the swivel bar.
Statistical analysis
The results were presented as mean ± SEM. The Graph-
Pad 5.0 software was used. Statistical analysis was car-
ried out using ANOVA (one or two-way) and the
Bonferroni test was used as a post-hoc test. The signifi-
cance level was p <0.05.
Results
Analysis of the possible mechanism of EPI’s
antinociceptive activity
The pretreatment of animals with the antagonists
naloxone (98.63±13.67, p< 0,001), glibenclamide (76.43±
13.80, p< 0,05), yoimbina (92.10±13.10, p< 0,001), pin-
dolol (92.68±15.93, p< 0,05) and atropine (98.45±13.07,
p< 0,05) completely reversed the antinociceptive effect of
EPI in the glutamate test (Figure 2A – 2E). However, there
was no reversal when the animals that received the EPI
were pretreated with the antagonists ondansetron, ketan-
serin and L-Arginine and caffeine (The data are not
shown). The MK presented a significant antinociceptive
effect in the protocols used.
Effect of EPI on the impairment of motor activity
The pretreatment of animals with EPI did not result
in reduction of motor activity in the Open Field
(73.85 ± 7.30) and Rotarod (50.54 ± 4.50) models when
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Figure 2 Possible mechanisms of EPI. Effect of pretreatment of animals with naloxone (2 mg/kg s.c Figure 2A), glibenclamide (2 mg/kg s.c
Figure 2B), yoimbine (0,15 mg/kg s.c Figure 2C), pindolol (1 mg/kg s.c Figure 2D) e atropine (0,2 mg/kg s.c Figure 2E) on the antinociceptive
profiles of the (−) epicatequin (EPI) administered orally against glutamate-induced nociception in mice. Each column represents the mean± S.E.M.
of 6 animals. Control value (C) indicates the animals treated with vehicle and the asterisks denote the significance levels, when compared with
control groups (one-way ANOVA followed by Bonferroni test) (*P< 0,005; **p< 0,01 e ***p< 0,001).
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reduction in motor activity when compared with control.
Discussion
EPI is primarily known for its antioxidant properties
and several studies have evaluated the use of this sub-
stance in the treatment of cardiovascular diseases and
as a cancer preventive. The possible antinociceptive ac-
tion of EPI has been demonstrated since it has the
ability to block sodium channels, structures that are
closely linked to the activation of sensory fibers [8].
The importance of our study is that it investigates themechanisms involved in the antinociceptive action of
EPI, contributes to the knowledge about the properties
of C. leprosum and its components, and may enable
the discovery of new therapeutic options for the treat-
ment of pain.
The activities of EPI were evaluated in a model of
glutamate-induced nociception. Glutamate promotes the
activation of NMDA receptors, causing an increased
influx of calcium with the activation of neuronal NO
synthase and nitric oxide formation. Thus, glutamate
participates in the processes involved in the perception
of and central sensitization to pain [12,13]. According
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in the central and peripheral nervous system [14,15].
Thus, blocking these receptors or decrease the re-
lease of glutamate would lead to a decrease in pain
perception. This effect was observed after the adminis-
tration of EPI. This blockage also justifies the results
found in other models such as capsaicin and formalin,
because previous studies show that there is an in-
creased level of glutamate due to the stimulation of C
fibers after application of capsaicin or formalin into the
paw [16-18].
An important result from our study was demonstrat-
ing the involvement of opioid receptors in the antinoci-
ceptive effect of EPI. The activation of central and
peripheral opioid receptors (mu and kappa mostly) is
linked to the inhibition of Ca++ currents and activation
of K+ currents through ATP-dependent channels via ac-
tivation of Gi. Moreover, these receptors reduce the acti-
vation of Na + channels and TRPV receptors, which also
contributes to the antinociceptive response of opioid
drugs [19].
In our study, we observed that the antinociceptive
action of EPI is reversed by naloxone antagonism,
which confirms the possible activation of opioid recep-
tors by EPI. This effect was also reversed by the ac-
tivity of glibenclamide, an antagonist of K + channels
sensitive to ATP, demonstrating the involvement of acti-
vation of these channels by EPI. This action was directly
related to the inhibition of nociceptive transmission.
Numerous studies show the importance of serotonin
(5-HT) in the regulating pathways and the inhibition of
nociception. This activity occurs through differentFigure 3 Possible mechanisms of EPI. The EPI could act through direct a
However, this action might be indirect through the inhibition of glutamatereceptors (5-HT1, 5-HT2, 5-HT3 and 5-HT4) where acti-
vation of the receptors 5HT1, 5HT2 and 5HT3 decreases
the nociceptive transmission in models such as the for-
malin one [6,18,20,21]. The results show that the antino-
ciceptive effect of EPI involves the participation of
5HT2A receptors, because we observed a reversal of this
effect when animals were pretreated with ketanserin or
pindolol, an antagonist of 5HT2A and 5HT1A, however,
this reversal has not been verified by pre-treatment with
ondansetron, which shows that there is no involvement
of 5HT3 receptors.
In turn, the serotonin system is related to the adrener-
gic system. The activation of 5-HT receptors may cause
an increased release of norepinephrine, which activates
the post synaptic alpha 2 receptor and leads to an inhib-
ition of painful impulse conduction. The activity of
antagonists such as yoimbina leads to a decreased anal-
gesic effect of the agonists of these receptors, for ex-
ample, clonidine [22,23]. On this basis, we suggest that
EPI presents its antinocicieptive effects through the acti-
vation of alpha 2 receptors because the pretreatment of
animals with yoimbina reversed its effects in the glutam-
ate model. The activation of alpha 2 receptors could also
lead to a decreased release of glutamate in afferent fibers
and this would further increase the action of EPI in the
studied model [24].
Likewise, the activation of these pathways activate
spinal cholinergic interneurons releasing acetylcholine
(ACh), which presents an antinociceptive effect prob-
ably due to the inhibition of glutamate release as well
as the release of GABA from pre-synaptic fibers by
the activation of muscarinic receptors antagonized byction on serotonin receptors, opioids, acetylcholine or noradrenaline.
release.
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tivity of EPI would partly justify its antinociceptive ef-
fects, because these were reversed by the atropine that
was previously administered to the mice in this model.
The activation of adenosine receptors (A1) is also
important in modulating pain. Agonists of these
receptors have significant antinociceptive effect that
can be reversed by caffeine or 8-phenyltheophylline
[26]. However, this mechanism does not participate in
EPI's activities, because pre-treatment with this antag-
onist did not reverse its effects. Another important
pathway in the modulation of nociception is the
pathway for nitric oxide. (NO) and cyclic guanosine
monophosphate (cGMP). The nitric oxide synthase
enzyme may be activated by NMDA glutamate recep-
tors, which leads to the formation of NO that is dir-
ectly related to the maintenance of nociception [13].
To assess the possible interference of EPI in the forma-
tion of NO, animals were pretreated with L-arginine, a
precursor of this substance. According to the results,
the antinociceptive effect of EPI does not involve the
NO/cGMP system as there was no reversal of the effect
in animals pretreated with L-arginine when compared
with the vehicle. The Figure 3, shows the possible sites
of action of EPI.
Conclusions
In conclusion, this study demonstrates that the antinoci-
ceptive activity of EPI in the glutamate model involves
the participation of the opioid system with potassium
channels sensitive to ATP, serotonin, adrenergic and
cholinergic.
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